- Home
- MNKD
MNKD
MannKind Corporation
as 11-15-2024 4:00pm EST
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | DANBURY |
| Market Cap: | 1.8B | IPO Year: | 2004 |
| Target Price: | $8.40 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.17 - $7.63 | Next Earning Date: | 11-07-2024 |
| Revenue: | $267,200,000 | Revenue Growth: | 51.35% |
| Revenue Growth (this year): | 46.83% | Revenue Growth (next year): | 14.40% |
Stock Insider Trading Activity of MannKind Corporation (MNKD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tross Stuart A | MNKD | Chief People & Workpl Officer | Nov 6 '24 | Sell | $7.34 | 55,000 | $403,700.00 | 967,191 | |
| Tross Stuart A | MNKD | Chief People & Workpl Officer | Sep 3 '24 | Sell | $6.26 | 25,000 | $156,500.00 | 967,191 | |
| Tross Stuart A | MNKD | Chief People & Workpl Officer | Aug 30 '24 | Sell | $6.33 | 80,000 | $506,050.00 | 967,191 | |
| Castagna Michael | MNKD | Chief Executive Officer | Aug 27 '24 | Sell | $6.30 | 85,106 | $536,167.80 | 2,294,836 | |
| Binder Steven B. | MNKD | EVP Special Projects | Aug 27 '24 | Sell | $5.94 | 5,055 | $30,026.70 | 1,075,026 | |
| Thomson David | MNKD | EVP Genl Counsel & Secretary | Aug 27 '24 | Sell | $5.94 | 5,553 | $32,984.82 | 829,843 |
Latest MannKind Corporation News
MNKD Breaking Stock News: Dive into MNKD Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Thomson Reuters StreetEvents
9 days ago
Q3 2024 MannKind Corp Earnings Call
GuruFocus.com
9 days ago
MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Motley Fool
9 days ago
MannKind (MNKD) Q3 2024 Earnings Call Transcript
Zacks
10 days ago
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
Zacks
10 days ago
MannKind (MNKD) Matches Q3 Earnings Estimates
Associated Press Finance
10 days ago
MannKind: Q3 Earnings Snapshot
GlobeNewswire
10 days ago
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
Compare MNKD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNKD MannKind Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.